Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jianaikang concentrated pill is a Traditional Chinese Medicine (TCM) formulation developed by the First Affiliated Hospital of Henan University of Chinese Medicine for the treatment of HIV infection. It is typically administered as part of a multi-component TCM regimen, which may include Yiaikang capsules and Tangcao tablets, aimed at delaying the progression of HIV to AIDS and improving the quality of life for patients on stable highly active antiretroviral therapy (HAART). The formulation is designed to stabilize CD4+ T-lymphocyte counts and modulate the immune response through its herbal constituents. As a concentrated pill (nongsuowan), it represents a modern TCM dosage form where herbal decoctions are concentrated and processed into small, dense pills for improved stability and patient compliance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on jianaikang concentrated pill.